Lantus Loss Drags Down Sanofi's Diabetes Franchise
This article was originally published in Scrip
Executive Summary
A nearly 20% drop in US sales of Sanofi's top-seller Lantus was largely to blame for a 6.6% fall in its diabetes franchise sales in the third quarter, leading the French pharma to lower its forecasts for its leading therapy segment.
You may also be interested in...
Sanofi CEO Upbeat Despite Medivation M&A Miss, Sarilumab Diss
During third-quarter earnings report, Brandicourt said he remains confident about Sanofi's prospects in oncology despite losing the takeover fight for Medivation, although he didn't rule out another mid-sized bolt-on attempt if the opportunity arose.
Sanofi Seeks Medivation Board Overhaul As Buyout Bid Remains Rejected
Sanofi is putting more pressure on Medivation to accept its $9.3bn acquisition offer by proposing to replace the biotechnology company's and Xtandi developer's entire board of directors.
10 Clinical Trials To Watch Out For In 2023
Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras. AstraZeneca, Novo Nordisk, Novartis and Roche feature heavily.